Jiuzhang Biotech has completed a Randomized, Controlled, Open-labeled, Multicenter Phase II/III Clinical Research on the Safety and Efficacy of the CHA for Injection for Recurrent Grade IV Glioblastoma (GBM). The company has also held EOPⅡ and pre‑Phase‑Ⅲ communication meetings with Chinese Center for Drug Evaluation, NMPA, reaching a consensus to proceed into Phase‑Ⅲ clinical trials.